At a glance

Paradigm Biopharma (PAR) listed on the ASX in August 2015. We focus on repurposing pentosan polysulphate sodium (PPS) for the treatment of conditions that begin with and are sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. Our lead clinical indications involve treating bone marrow edema (BME), an increasingly recognised pathological change in bone and a significant contributor to pain and symptoms in Osteoarthritis and acute joint injury.

Other indications include treating alphavirus induced arthralgia (in patients with Ross River Virus and Chikungunya); and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).

Adopting an intelligent and agile approach to clinical research and development, our experienced team are passionate in our commitment to the quality of our programmes. We have built and sustained strong and successful collaborations with leading clinical researchers in the field, and continue to develop partnerships with high quality European manufacturers in order to bring new, effective treatments to market.

Repurposing PPS

The cost and complexity of starting with a new molecule led us to explore the possibility of finding a simpler path to treating complex disease.

This led us to explore repurposing PPS, an FDA approved drug that has a long track record of treating inflammation, but which had been used narrowly to treat bladder inflammation (interstitial cystitis) and for preventing deep vein thrombosis.

By working closely with the proprietary manufacturer of PPS, we are able to leverage substantial knowledge and expertise available from earlier regulatory filings

This involves decades of accumulated toxicology safety data, manufacturing ‘know how’, and extensive published information about PPS’s mechanisms of action, which primarily involves interactions with proteins impacting inflammation. With this foundation, Paradigm Biopharma minimises its risk profile as an early stage drug development company. We already see shortened drug development cycle time for our chosen applications and development costs minimised.